BioShaf promises one-step fertility testing:
This article was originally published in Clinica
Executive Summary
Israeli firm BioShaf has developed an automated, one-step system that can test for infertility in both men and women. The BioShaf system, which comprises a compact and inexpensive flowcytometer, will enable laboratories and fertility clinics to perform the most commonly requested fertility tests on a single instrument in less than two hours. The product avoids the costs of multiple laboratory equipment and skilled labour needed for conventional infertility testing methods, while increasing throughput and consistency of results, says the Tel-Hannan firm. Applications to market the system in the US and Europe are underway.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.